Remington Pharmaceutical Book

[Emir Ballard]

Formore than 100 years, Remington has been the definitive reference for all aspects of the science and practice of pharmacy and is used for pharmaceutics, therapeutics, and pharmacy practice courses in primary curricula. Since the first edition was published, pharmacists have used this book as a comprehensive one-stop reference.

Remington: The Science & Practice of Pharmacy is the most widely used textbook and reference work on pharmaceutical sciences in the nation. Publication of the text was begun as Practice of Pharmacy in 1886 by Joseph Price Remington, professor and later dean at the University. Subsequent to his death, the copyright to this text was assigned to the Philadelphia College of Pharmacy (now Saint Joseph's University) by the heirs of Professor Remington.

Remington has provided a comprehensive source of knowledge about the science and practice of pharmacy. The book provides information to help both students and practitioners serve effectively as members of the health professions team. The 22nd edition was published in 2012.

This special bicentennial edition, edited by Professor of Pharmaceutical Sciences Adeboye Adejare Ph.D., celebrates 200 years since the founding of Philadelphia College of Pharmacy in 1821. The founding of the college is regarded as the beginning of pharmacy education and modern pharmacy practice. The text also addresses modern challenges including COVID-19, substance use disorders and medical cannabis.

The 22nd edition of Remington offers a unique array of content in two volumes, covering pharmaceutical science and pharmaceutical practice. Its value is immense for students and practitioners in all areas of the discipline.

Remington: The Science and Practice of Pharmacy, Twenty Third Edition, offers a trusted, completely updated source of information for education, training, and development of pharmacists. Published for the first time with Elsevier, this edition includes coverage of biologics and biosimilars as uses of those therapeutics have increased substantially since the previous edition. Also discussed are formulations, drug delivery (including prodrugs, salts, polymorphism. With clear, detailed color illustrations, fundamental information on a range of pharmaceutical science areas, and information on new developments in industry, pharmaceutical industry scientists, especially those involved in drug discovery and development will find this edition of Remington an essential reference. Intellectual property professionals will also find this reference helpful to cite in patents and resulting litigations. Additional graduate and postgraduate students in Pharmacy and Pharmaceutical Sciences will refer to this book in courses dealing with medicinal chemistry and pharmaceutics.

The vision of our esteemed Chairman, Dr. Abdul Qadeer Khokhar, to provide medicines of world-class quality to the People of Pakistan & Beyond for putting Pakistan on the global pharmaceutical map, has made this feat possible.

The company with its set goal of achieving approvals from Global Stringent Regulatory Authorities (SRA), is well on its way to obtain MHRA, EMA, PIC/s and other SRA approvals for multiple dosage forms including, oral solids (tablets, capsules and dry suspensions), sachets, sterile ophthalmic preparations, nasal sprays, and oral liquids.

We are equally thankful to the Drug Regulatory Authority (DRAP) of Pakistan and Ministry of National Health Services Regulations and Coordination for supporting us exceptionally in this important project of national importance.

And utmost compliments to all Team Remington; who showed that if we set our sight on any target, together we achieve it as ONE TEAM. Future holds great ventures for us as an Organization, as a Team and collectively as a Nation!

With over four decades of serving healthcare needs and a vision to enhance the quality of life, Remington Pharmaceuticals is committed to providing best healthcare solutions. Remington is best known for its dedicated people, passion for innovation through Research & Development and quality healthcare solutions.

Remington is consistently the Market Leader in select therapeutic segments and have one of the largest manufacturing facilities in the country coupled with strict cGMP compliance in accordance with WHO, EMA, ISPE guidelines.

NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

"TB Alliance is proud to partner with a leading healthcare solutions company in Pakistan to help ensure this treatment is available and accessible to those who need it throughout the country," said Mel Spigelman, President and CEO of TB Alliance. "This exciting update ensures an affordable and sustainable market for state-of-the-art therapies for drug-resistant TB in Pakistan."

"Pakistan is dedicated to eliminating TB and drug-resistant TB as public health threats. We applaud Remington Pharmaceuticals and TB Alliance for partnering to bring this medication to those affected with TB, and our government will work diligently to make sure that patients throughout the country can access the BPaL and BPaLM regimens," said Dr. Abdul Baseer Khan Achakzai, Director General of Health, Ministry of National Health Services, Pakistan.

"Remington is proud and thrilled to collaborate with TB Alliance to provide solutions that could change the lives of drug-resistant TB patients in Pakistan. Being the first national pharmaceutical company to attain WHO Prequalification from Pakistan, we strive to make quality TB products accessible to all. We are committed to the fight against tuberculosis and this partnership will support our global efforts to eliminate this disease efficiently. Our established distribution pathways will help doctors reach patients throughout the country," said Dr. Abdul Qadeer Khokhar, Chairman of Remington Pharmaceuticals.

The partnership with Remington is part of TB Alliance's global commercialization strategy for pretomanid as part of the BPaL/BPaLM regimens. This agreement is meant to complement four previously announced partnerships with manufacturers who were strategically recruited to ensure adequate quantities of quality assured product globally, and to enable market competition to ensure pretomanid is affordable for all countries.

About TB AllianceTB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia's Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Cystic Fibrosis Foundation, European & Developing Countries Clinical Trials Partnership, Germany's Federal Ministry of Education and Research through KfW, Global Health Innovative Technology Fund, Indonesia Health Fund, Innovative Medicines Initiative, Irish Aid, National Institute of Allergy and Infectious Disease, United Kingdom Department for International Development, and the United States Agency for International Development. For more information, please visit: www.tballiance.org.

About Remington PharmaceuticalsRemington Pharmaceuticals, a leading branded generic pharmaceutical company with 45 years of history, is focused on improving the quality of human life. Operating with manufacturing facilities in Pakistan and its international office in Dubai, the company is committed to continuous innovation in developing medicinal and nutritional products.

Among the medical professionals and other stakeholders, Remington Pharmaceuticals is best known for its quality healthcare solutions, passion for innovation through research and development, and dedicated people. Remington is the first national pharmaceutical company to obtain WHO Prequalification approval for an anti-TB product and is the only partner of Medicine Patent Pool for treatments of infectious diseases.

Remington Pharmaceuticals has a state-of-the-art cGMP-compliant manufacturing facility with large capacities for manufacturing tablets, capsules, sterile drops, sterile ointments, syrups, powder, and external preparations.

Maine previously served as Senior Vice President for Policy, Planning, and Communication and in other roles at APhA from 1992 to 2002. She also served as Interim Dean, Associate Dean for Student/Alumni Affairs and Director of Professional Relations and Assistant Professor of Pharmacy Practice at Samford University School of Pharmacy from 1986 to 2001. Maine has delivered over 200 research and practice development programs during her time at AACP and APhA as well as commencement addresses at colleges and schools of pharmacy. She also has published numerous editorials, committee reports, research and professional articles, and book chapters.

Her previous awards from APhA include recognition as a Fellow of APhA in 2003 and the APhA Franke Mentorship Award in 2018, APhA Foundation Jacob Miller Award in 2009, and APhA Academy of Students of Pharmacy Linwood F. Tice Award in 2004. Maine also was inducted into the Alabama Pharmacy Hall of Fame in 2017 and recognized as a Fellow of the International Pharmaceutical Federation (FIP) in 2014, along with countless other honors. Maine received her pharmacy degree at Auburn University and her Kellogg Pharmaceutical Clinical Scientist Ph.D. in the College of Pharmacy at the University of Minnesota. Maine has also received honorary doctorates from Western University and Ohio Northern University.

3a8082e126